← All Amylyx Pharmaceuticals, INC filings

Amylyx Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
AMLX
Amylyx Pharmaceuticals, INC
10-K: Amylyx Pivots Post-ALS Drug Withdrawal, Boosts Pipeline
Amylyx Pharmaceuticals reports a strategic shift following the withdrawal of its ALS drug, focusing on a pipeline of novel therapies for endocrine and neurodegenerative diseases, supported by significant capital raises.
NASDAQ
AMLX
Amylyx Pharmaceuticals, INC
10-K: Amylyx Pharmaceuticals Navigates Strategic Shift: 2024 10-K Highlights Pipeline Focus Amidst Market Exit
Amylyx Pharmaceuticals' 2024 10-K filing details a strategic pivot, emphasizing pipeline development after ceasing sales of RELYVRIO/ALBRIOZA, alongside financial results and future outlook.
NASDAQ
AMLX
Amylyx Pharmaceuticals, INC
10-K: Amylyx Pharmaceuticals Reports Strong Revenue Growth in 2023, Eyes Expansion
Amylyx Pharmaceuticals generated $403 million in net product revenue in 2023 from its ALS treatments, RELYVRIO and ALBRIOZA, and is advancing clinical trials for other neurodegenerative diseases.